Marathon Pharma Group signed an agreement to acquire a controlling stake in Fort LLC, a biopharmaceutical company that is a part of Nacimbio of Rostec Corporation. The deal must be closed by the end of the summer.
Fort plant is a major manufacturer of vaccines against influenza. In 2017, it is expected to supply about 18 million doses for vaccinations under the National Immunization Calendar.
“In three years since the opening of the plant, we have achieved good results. Today, Fort is a serious player in the vaccine market, said Anton Katlinsky, a co-owner of FORT LLC. The arrival of strategic investor is a new stage in the development of this project. We expect that, together with our partners, we will implement the groundwork of our team, expand our product portfolio, and deploy technologies that are unique for Russia.”
It is expected that, in 2017, the plant will generate the revenues of more than 2.2 billion rubles.
The acquisition of the plant fits into the development strategy of Marathon Pharma manufacturing unit, which already includes JSC Joint-Stock Kurgan Company of Medicinal Products and Devices Sintez, JSC Biocom, and Bentus Laboratories LLC.